Overview
ACET market data
Price History
ACET price chart · 1M
- O
- 9.55
- H
- 9.55
- L
- 9.53
- C
- 9.53
- Vol
- 200.00
- Source
- US equities market feed
- Observed
- Sep 4, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $9.55
- Previous Close
- $9.62
- Day High
- $9.55
- Day Low
- $9.53
- 52 Week High
- $9.76
- 52 Week Low
- $7.02
- 7 Day Return
- +5.25%
- 30 Day Return
- +4.33%
- 90 Day Return
- +31.20%
- 1 Year Return
- +13.33%
- Daily Notional Volume
- $1.9K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.33 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -93.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.01 – $17.44 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $88.3M · P/B 0.51 · P/S 2.28.
Company News
6 captured
Adicet Bio Announces Completion Of Last Patient Visit For 22-Patient Phase 1 Analysis Of Prula-Cel In Systemic Lupus Erythematosus; Says Topline Data Expected September 2026Benzinga · Sep 1, 2026, 11:03 AM
8-K filing — Adicet Bio, Inc. (ACET)SEC EDGAR · Sep 1, 2026, 11:02 AM
Adicet Bio Reveals FDA Clearance Of IND Application For ADI-212; Co Plans To Initiate Phase 1 Enrollment In Patients With mCRPC In Q4 Of 2026Benzinga · Aug 27, 2026, 8:02 PM
Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $90Benzinga · Aug 6, 2026, 1:51 PM
Adicet Bio Q2 EPS $(1.99) Beats $(2.03) EstimateBenzinga · Aug 5, 2026, 10:08 PM
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsightGlobenewswire Inc · Jun 10, 2026, 5:15 PM